Emilie Chalayer

Dr. Emilie Chalayer

SAINBIOSE INSERM UJM
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 July 2014 in SpringerPlus
Verified
Journal Article
Open access
PDF file
ECEmilie Chalayer
Emilie Chalayer
MFMartine Ffrench
Martine Ffrench
PCPascal Cathébras
Pascal Cathébras
Peripheral cytopenias are common in systemic lupus erythematosus (SLE), but bone marrow involvement is rarely reported. Myelofibrosis is a rare disorder characterized by reticulin fibrosis of the bone marrow, which usually occurs in response to clonal proliferation of hematopoietic stem cells in myeloproliferative disorders. However, bone marrow fibrosis has also been described in association with auto-immune diseases, especially SLE. We will report here a new case of bone marrow fibrosis associated with SLE. We also reviewed the 27 cases published in the English language literature, and will discuss the clinical presentation, outcome, treatment, and pathophysiology of bone marrow fibrosis occurring in association with SLE. Over one half of patients were diagnosed concomitantly with bone marrow fibrosis and SLE. Epidemiological, clinical and biological features of lupus were unremarkable. Except for the presence of reticulin fibrosis, the findings from the bone marrow biopsies proved highly variable. Overall mortality was about 14% but corticosteroid-based therapy lead to clinical improvement and reverted bone marrow fibrosis in most cases. Data on the usefulness of other immunomodulatory therapies are inconclusive. SLE may be complicated by bone marrow involvement, of a likely autoimmune origin. Bone marrow fibrosis occurring with SLE is probably similar to “primary autoimmune myelofibrosis” and may respond to steroid and immunomodulatory therapies. Further studies with standardised proofreading of bone marrow aspirations and biopsies are needed to delineate the clinical and biological features of this rare complication of SLE.

16 July 2019 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
BTBernard Tardy
Bernard Tardy
ECEmilie Chalayer
Emilie Chalayer
PKPieter Willem Kamphuisen
Pieter Willem Kamphuisen
FAFionnuala Ni Ainle
Fionnuala Ni Ainle
PVPeter Verhamme
Peter Verhamme
TIThe Ssc Subcommittee On Control Of Anticoagulation Of The Isth
The Ssc Subcommittee On Control Of Anticoagulation Of The Isth

1 February 2021 in La Revue de Médecine Interne
Verified
Journal Article
Closed access
AGA. Genthon
A. Genthon
MKM. Killian
M. Killian
PMP. Mertz
P. Mertz
PCP. Cathebras
P. Cathebras
SMS. Gimenez De Mestral
S. Gimenez De Mestral
ECEmilie Chalayer
Emilie Chalayer

30 October 2014 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
ECEmilie Chalayer
Emilie Chalayer
MFMartine Ffrench
Martine Ffrench
PCPascal Cathébras
Pascal Cathébras

13 December 2018 in Research and Practice in Thrombosis and Haemostasis
Verified
Journal Article
Open access
PDF file
ECEmilie Chalayer
Emilie Chalayer
BTBrigitte Tardy‐Poncet
Brigitte Tardy‐Poncet
LKLionel Karlin
Lionel Karlin
CCCéline Chapelle
Céline Chapelle
AMAurélie Montmartin
Aurélie Montmartin
BTBernard Tardy
Bernard Tardy
Background Multiple myeloma (MM) is associated with a high risk of thrombosis, particularly during the first months of treatment including immunomodulatory drugs (IMiDs). There is no consensus on prevention of thromboembolic risk in patients with de novo MM, and identification of patients requiring anticoagulant thromboprophylaxis remains challenging. Evaluating coagulability by an in vitro thrombin generation (TG) test might be a way of identifying such patients. Objective To determine whether TG assessment could reveal an increase in coagulability during the first three chemotherapy cycles. Methods This prospective and longitudinal observational study included patients newly diagnosed with MM. TG was determined in platelet‐rich and platelet‐poor plasma using calibrated automated thrombography with a low tissue factor (TF) concentration. Results Seventy‐one patients were enrolled, allowing TG analysis during 213 chemotherapy cycles. TG remained unchanged throughout follow‐up irrespective of treatment regimen, but values determined before cycles 2 and 3 were significantly higher in patients receiving iMiDs‐containing regimens. No association was found between TG and its changes and thrombosis occurrence during follow‐up: venous thrombosis in eight patients; no cardiovascular event. A significantly (87%) lower risk of venous thrombosis was observed in patients receiving prophylaxis with a low‐molecular‐weight heparin (LMWH; OR: 0.13 (95% CI: 0.02‐0.76). Neither bortezomib‐ nor dexamethasone‐containing regimens were associated with thrombotic risk. Changes in TG, as studied, were not associated with thrombotic events. Conclusions The only factor associated with a reduction in early thrombotic risk was prophylaxis with LMWH. The issue of how to identify patients requiring prophylactic anticoagulation remains unresolved.

12 May 2022 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Closed access
ECEmilie Chalayer
Emilie Chalayer
ATAlexis Talbot
Alexis Talbot
LFLaurent Frenzel
Laurent Frenzel
LKLionel Karlin
Lionel Karlin
PCPhilippe Collet
Philippe Collet
BTBernard Tardy
Bernard Tardy